# US 2024/0002843 A1 · Compositions and methods for the treatment of hemoglobinopathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002843 A1
- Document ID: US20240002843A1
- Status: Published application
- Kind: A1
- Application number: 17/965,366
- Filed: 2022-10-13
- Published: 2024-01-04
- Earliest claimed: 2015-12-28
- Assignees: Novartis AG; Intellia Therapeutics, Inc.
- Applicants: Novartis AG; Intellia Therapeutics, Inc.
- Inventors: Anthony Edward BOITANO; Michael COOKE; Lloyd B. KLICKSTEIN; Reynald LESCARBEAU; Craig Stephen MICKANIN; Kabungo MULUMBA; Seshidhar Reddy POLICE; Jennifer SNEAD; Susan C. STEVENSON; Morag STEWART; Yi YANG
- Web page: https://patentgrep.com/patent/US20240002843A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 40/10: characterised by the cell type used
- A61K 40/40: characterised by antigens that are targeted or presented by cells of the immune system
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12N 2310/10: Type of nucleic acid
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.

## Claims

### Claim at position 1

-230. (canceled)

### Claim 231

A gRNA molecule comprising a tracr and crRNA, wherein the crRNA comprises a targeting domain that is complementary with a target sequence of a human BCL11a gene, a human BCL11a enhancer, or a human HPFH region, wherein
(a) the target sequence is of the human BCL11a gene, and the targeting domain comprises any one of SEQ ID NO: 1 to SEQ ID NO: 85 or SEQ ID NO: 400 to SEQ ID NO: 1231, or a fragment thereof;
(b) the target sequence is of the human BCL11a enhancer, and the targeting domain comprises any one of SEQ ID NO: 182 to SEQ ID NO: 277, or SEQ ID NO: 278 to SEQ ID NO: 333, or SEQ ID NO: 334 to SEQ ID NO: 341, or SEQ ID NO: 1232 to SEQ ID NO: 1499, or SEQ ID NO: 1596 to SEQ ID NO: 1691, or a fragment thereof; or
(c) the target sequence is of the human HFPH region, and the targeting domain comprises any one of SEQ ID NO: 86 to SEQ ID NO: 181, SEQ ID NO: 1500 to SEQ ID NO: 1595, or SEQ ID NO: 1692 to SEQ ID NO: 1761, or a fragment thereof.

### Claim 232 (depends on 231)

The gRNA molecule of claim 231, wherein,
(a) the targeting domain comprises any one of SEQ ID NO: 338, SEQ ID NO: 248, SEQ ID NO: 253, SEQ ID NO: 341, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 245, SEQ ID NO: 249, SEQ ID NO: 244, SEQ ID NO: 199, SEQ ID NO: 251, SEQ ID NO: 250, SEQ ID NO: 334, SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 335, SEQ ID NO: 336, or SEQ ID NO: 337, or a fragment thereof;
(b) the targeting domain comprises any one of SEQ ID NO: 318, SEQ ID NO: 312, SEQ ID NO: 313, SEQ ID NO: 294, SEQ ID NO: 310, SEQ ID NO: 319, SEQ ID NO: 298, SEQ ID NO: 322, SEQ ID NO: 311, SEQ ID NO: 315, SEQ ID NO: 290, SEQ ID NO: 317, SEQ ID NO: 309, SEQ ID NO: 289, or SEQ ID NO: 281, or a fragment thereof;
(c) the targeting domain comprises any one of SEQ ID NO: 1683, SEQ ID NO: 1638, SEQ ID NO: 1647, SEQ ID NO: 1609, SEQ ID NO: 1621, SEQ ID NO: 1617, SEQ ID NO: 1654, SEQ ID NO: 1631, SEQ ID NO: 1620, SEQ ID NO: 1637, SEQ ID NO: 1612, SEQ ID NO: 1656, SEQ ID NO: 1619, SEQ ID NO: 1675, SEQ ID NO: 1645, SEQ ID NO: 1598, SEQ ID NO: 1599, SEQ ID NO: 1663, SEQ ID NO: 1677, or SEQ ID NO: 1626, or a fragment thereof; or
(d) the targeting domain comprises any one of SEQ ID NO: 100, SEQ ID NO: 165, SEQ ID NO: 113, SEQ ID NO: 99, SEQ ID NO: 112, SEQ ID NO: 98, SEQ ID NO: 1505, SEQ ID NO: 1580, SEQ ID NO: 106, SEQ ID NO: 1503, SEQ ID NO: 1589, SEQ ID NO: 160, SEQ ID NO: 1537, SEQ ID NO: 159, SEQ ID NO: 101, SEQ ID NO: 162, SEQ ID NO: 104, SEQ ID NO: 138, SEQ ID NO: 1536, SEQ ID NO: 1539, SEQ ID NO: 1585, SEQ ID NO: 1700, or SEQ ID NO: 1750, or a fragment thereof.

### Claim 233 (depends on 231)

The gRNA molecule of claim 231, comprising, from 5′ to 3′, [the targeting domain]—:
(a) SEQ ID NO: 6601;
(b) SEQ ID NO: 6602;
(c) SEQ ID NO: 6603;
(d) SEQ ID NO: 6604;
(e) SEQ ID NO: 7811; or
(f) any of (a) to (e), above, further comprising, at the 3′ end, 1, 2, 3, 4, 5, 6 or 7 uracil (U) nucleotides.

### Claim 234 (depends on 231)

The gRNA molecule of claim 231, wherein one or more nucleic acid molecules of the gRNA molecule comprise:
(a) one or more phosphorothioate modifications at the 3′ end of said one or more nucleic acid molecules;
(b) one or more phosphorothioate modifications at the 5′ end of said one or more nucleic acid molecules;
(c) one or more 2′-O-methyl modifications at the 3′ end of said one or more nucleic acid molecules;
(d) one or more 2′-O-methyl modifications at the 5′ end of said one or more nucleic acid molecules;
(e) a 2′-O-methyl modification at each of the 4th-to-terminal, 3rd-to-terminal, and 2nd-to-terminal 3′ residues of said one or more nucleic acid molecules;
(f) a 2′-O-methyl modification at each of the 4th-to-terminal, 3rd-to-terminal, and 2nd-to-terminal 5′ residues of said one or more nucleic acid molecules; or
(g) any combination thereof.

### Claim 235 (depends on 231)

The gRNA molecule of claim 231, comprising:
(a) SEQ ID NO: 342;
(b) SEQ ID NO: 343;
(c) SEQ ID NO: 1762;
(d) a crRNA comprising SEQ ID NO: 344, and a tracr comprising SEQ ID NO: 6660;
(e) a crRNA comprising SEQ ID NO: 344, and a tracr comprising SEQ ID NO: 346;
(f) a crRNA comprising SEQ ID NO: 345, and a tracr comprising SEQ ID NO: 6660;
(g) a crRNA comprising SEQ ID NO: 345, and a tracr comprising SEQ ID NO: 346;
(h) SEQ ID NO: 347;
(i) SEQ ID NO: 348;
(j) SEQ ID NO: 1763;
(k) a crRNA comprising SEQ ID NO: 349, and a tracr comprising SEQ ID NO: 6660;
(l) a crRNA comprising SEQ ID NO: 349, and a tracr comprising SEQ ID NO:
(m) a crRNA comprising SEQ ID NO: 350, and a tracr comprising SEQ ID NO: 6660; or
(n) a crRNA comprising SEQ ID NO: 350, and a tracr comprising SEQ ID NO: 346.

### Claim 236 (depends on 231)

A composition comprising:
(a) one or more gRNA molecules of claim 231 and a Cas9 molecule;
(b) one or more gRNA molecules of claim 231 and a polynucleotide comprising a nucleic acid sequence encoding a Cas9 molecule;
(c) a nucleic acid sequence encoding one or more gRNA molecules of claim 231 and a Cas9 molecule;
(d) a polynucleotide comprising a nucleic acid sequence encoding one or more gRNA molecules of claim 231 and a polynucleotide comprising a nucleic acid sequence encoding a Cas9 molecule; or
(e) any of (a) to (d) above, and a template nucleic acid; or
(f) any of (a) to (d) above, and a polynucleotide comprising a nucleic acid sequence encoding a template nucleic acid.

### Claim 237 (depends on 236)

The composition of claim 236, wherein the Cas9 molecule is an active or inactive S. pyogenes Cas9.

### Claim 238 (depends on 236)

The composition of claim 236, wherein the Cas9 molecule comprises SEQ ID NO: 6611, or a sequence with at least 95% sequence homology thereto.

### Claim 239 (depends on 236)

The composition of claim 236, wherein the Cas9 molecule comprises:
(a) SEQ ID NO: 7821;
(b) SEQ ID NO: 7822;
(c) SEQ ID NO: 7823;
(d) SEQ ID NO: 7824;
(e) SEQ ID NO: 7825;
(f) SEQ ID NO: 7825, further comprising a leucine at position 88 (C88L) of SEQ ID NO: 7825, and comprising a glutamic acid at position 582 (C582E) of SEQ ID NO: 7825;
(g) SEQ ID NO: 7826;
(h) SEQ ID NO: 7827;
(i) SEQ ID NO: 7828;
(j) SEQ ID NO: 7829;
(k) SEQ ID NO: 7830; or
(l) SEQ ID NO: 7831.

### Claim 240 (depends on 231)

A polynucleotide comprising a nucleic acid sequence that encodes one or more gRNA molecules of claim 231.

### Claim 241 (depends on 240)

A vector comprising the polynucleotide of claim 240.

### Claim 242 (depends on 231)

A method of altering a cell at or near the target sequence of one or more gRNA molecules within said cell, comprising contacting said cell with:
(a) one or more gRNA molecules of claim 231 and a Cas9 molecule;
(b) one or more gRNA molecules of claim 231 and a polynucleotide comprising a nucleic acid sequence encoding a Cas9 molecule;
(c) a polynucleotide comprising a nucleic acid sequence encoding said one or more gRNA molecules of claim 231 and a Cas9 molecule;
(d) a polynucleotide comprising a nucleic acid sequence encoding said one or more gRNA molecules of claim 231 and a polynucleotide comprising a nucleic acid sequence encoding a Cas9 molecule;
(e) any of (a) to (d) above, and a template nucleic acid; or
(f) any of (a) to (d) above, and a polynucleotide comprising a nucleic sequence encoding a template nucleic acid.

### Claim 243 (depends on 242)

The method of claim 242, wherein the cell is a mammalian, primate, or human cell.

### Claim 244 (depends on 243)

The method of claim 243, wherein the cell is a hematopoietic stem or progenitor cell (HSPC); a CD34+ cell; a CD34+CD90+ cell; a cell disposed in a composition comprising a population of cells that has been enriched for CD34+ cells; a cell that has been isolated from bone marrow, mobilized peripheral blood, or umbilical cord blood.

### Claim 245 (depends on 242)

The method of claim 242, wherein the altering results in an indel at or near the target sequence of the one or more gRNA molecules.

### Claim 246 (depends on 231)

A cell, comprising a gRNA molecule of claim 231 and a Cas9 molecule.

### Claim 247 (depends on 246)

The cell of claim 246, wherein the Cas9 molecule comprises:
(a) SEQ ID NO: 7821;
(b) SEQ ID NO: 7822;
(c) SEQ ID NO: 7823;
(d) SEQ ID NO: 7824;
(e) SEQ ID NO: 7825;
(f) SEQ ID NO: 7825, further comprising a leucine at position 88 (C88L) of SEQ ID NO: 7825, and comprising a glutamic acid at position 582 (C582E) of SEQ ID NO: 7825;
(g) SEQ ID NO: 7826;
(h) SEQ ID NO: 7827;
(i) SEQ ID NO: 7828;
(j) SEQ ID NO: 7829;
(k) SEQ ID NO: 7830; or
(l) SEQ ID NO: 7831.

### Claim 248 (depends on 246)

The cell of claim 246, wherein expression of fetal hemoglobin is increased in said cell or its progeny relative to a cell or its progeny of the same cell type that does not comprise the gRNA molecule.

### Claim 249

A cell comprising an indel shown in FIG. 25, Table 15, Table 26, Table 27, or Table 37.

### Claim 250 (depends on 246)

A population of cells comprising the cell of claim 246.

### Claim 251 (depends on 231)

A method of preparing a population of human cells, comprising:
(a) providing a population of human cells;
(b) culturing said population of human cells ex vivo in a cell culture medium comprising a stem cell expander; and
(c) introducing into said human cells of said population of human cells a gRNA molecule of claim 231 or a nucleic acid molecule encoding a gRNA molecule of claim 231.

### Claim 252 (depends on 251)

The method of claim 251, wherein the indel in each of said cells of the population of cells is an indel shown in FIG. 25, Table 15, Table 26, Table 27 or Table 37.
